Cardiovascular gene therapy
Part 1. Genetics
1.7. Gene Therapy
Published Online: 15 JAN 2005
Copyright © 2005 John Wiley & Sons, Ltd
Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics
How to Cite
Bhardwaj, S., Roy, H. and Ylä-Herttuala, S. 2005. Cardiovascular gene therapy. Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics. 1:1.7:94.
- Published Online: 15 JAN 2005
A variety of treatment modalities are presently available for the treatment of cardiovascular diseases either in the form of drug therapy or surgical intervention. A relatively new field of gene therapy for cardiovascular diseases is fast evolving. The diseases in focus are atherosclerosis, coronary and peripheral arterial diseases, coronary restenosis, and vein graft diseases. Promising results have been obtained in animal models of restenosis and vein graft thickening with transfer of genes encoding VEGF, nitric oxide synthatase, thymidine kinase, tissue inhibitors of metalloproteinases, and antisense oligonucleotides against transcription factors or cell cycle regulatory proteins. VEGF and FGF gene transfer have been successfully used in improving blood flow and development of collateral arteries in peripheral vascular disease and myocardial ischemic conditions. Here, we present a synopsis of the potential treatment genes, their therapeutic targets, mode of delivery, human clinical trials, and limitations encountered in the field of cardiovascular gene therapy.
- angiogenic factors;
- gene therapy;